Banked Cord Tissue MSCs
Multiple Sclerosis
Key Facts
About Cryo-Cell
Cryo-Cell's mission is to provide families with secure, high-quality preservation of newborn stem cells for potential future therapeutic use. The company's core achievement is establishing itself as a leader in the private cord blood banking industry, serving nearly half a million parents globally since its founding in 1989 and maintaining a strong transplant record. Its strategy centers on leveraging its proprietary PrepaCyte-CB processing technology to offer a superior cell product, while exploring the expansion of its service model through research into new clinical applications for banked cells. The company aims to transition from a pure storage service to a more integrated player in the regenerative medicine ecosystem.
View full company profileAbout Cryo-Cell
Cryo-Cell's mission is to provide families with secure, high-quality preservation of newborn stem cells for potential future therapeutic use. The company's core achievement is establishing itself as a leader in the private cord blood banking industry, serving nearly half a million parents globally since its founding in 1989 and maintaining a strong transplant record. Its strategy centers on leveraging its proprietary PrepaCyte-CB processing technology to offer a superior cell product, while exploring the expansion of its service model through research into new clinical applications for banked cells. The company aims to transition from a pure storage service to a more integrated player in the regenerative medicine ecosystem.
View full company profileAbout Cryo-Cell
Cryo-Cell's mission is to provide families with secure, high-quality preservation of newborn stem cells for potential future therapeutic use. The company's core achievement is establishing itself as a leader in the private cord blood banking industry, serving nearly half a million parents globally since its founding in 1989 and maintaining a strong transplant record. Its strategy centers on leveraging its proprietary PrepaCyte-CB processing technology to offer a superior cell product, while exploring the expansion of its service model through research into new clinical applications for banked cells. The company aims to transition from a pure storage service to a more integrated player in the regenerative medicine ecosystem.
View full company profileTherapeutic Areas
Other Multiple Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| SPU-16 | Silo Pharma | Preclinical |
| Electroceutical® Therapy | Endonovo Therapeutics | Research |
| BTK allosteric inhibitor | Acellera | Pre-clinical |
| CLS12311 | Cellerys | Phase 2 |
| Interferon-beta variants | Heligenics | Pre-clinical |
| G-NK cells | Indapta Therapeutics | Phase 1 |
| MS Biomarker Research | Rune Labs | Research |
| AVT001 | Avotres | Phase 2b |
| Undisclosed MS Program | Astoria Biologica | Pre-clinical |
| PV-3212 | Provid Pharma | Pre-clinical |
| Evobrutinib | EMD Serono | Phase 3 |
| REBIF (interferon beta-1a) | EMD Serono | Approved |